Free Republic

Sen. Rand Paul revealed Wednesday in a disclosure that was more than a year overdue that his wife in February 2020 bought up to $15,000 worth of shares in Gilead, a biotech company that brought to market the first drug designed to treat COVID-19. Paul’s mandatory filing with the Senate shows that his wife purchased between $1,000 and $15,000 worth of Gilead stock on Feb. 26, 2020. Gilead’s antiviral drug remdesivir became the first COVID-19 specific treatment to win an emergency use authorization from the Food and Drug Administration less that three months after the purchase in May 2020.

A retracted study on hydroxychloroquine and news that the coronavirus may be mutating drew reactions Friday night from Fox News medical contributor Dr. Marc Siegel. "So Lancet, with egg on its face, a renowned journal, is suddenly withdrawing this study," Siegel noted during an appearance on "Tucker Carlson Tonight" A database by Surgisphere Corp. of Chicago was used in an observational study of nearly 100,000 patients that appeared May 22 in The Lancet, an influential medical journal. The study tied the malaria drugs hydroxychloroquine and chloroquine to a higher risk of death in hospitalized patients with the virus. The validity...

GILEAD SCIENCES’ REMDESIVIR has been heralded as our best hope in fighting the coronavirus pandemic. Unfortunately, the antiviral drug doesn’t seem of much help to patients with Covid-19, the disease caused by the coronavirus. And while the company’s clever rollout has generated excitement among investors, politicians, and the public, a combination of generic drugs that appears to be more effective in fighting the coronavirus has flown under the radar.